KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amneal Pharmaceuticals (AMRX) Tax Provisions (2017 - 2025)

Amneal Pharmaceuticals has reported Tax Provisions over the past 9 years, most recently at $5.7 million for Q4 2025.

  • Quarterly results put Tax Provisions at $5.7 million for Q4 2025, up 4.41% from a year ago — trailing twelve months through Dec 2025 was $11.3 million (down 40.22% YoY), and the annual figure for FY2025 was $11.3 million, down 40.22%.
  • Tax Provisions for Q4 2025 was $5.7 million at Amneal Pharmaceuticals, up from -$23.4 million in the prior quarter.
  • Over the last five years, Tax Provisions for AMRX hit a ceiling of $16.1 million in Q2 2025 and a floor of -$23.4 million in Q3 2025.
  • Median Tax Provisions over the past 5 years was $4.0 million (2021), compared with a mean of $3.0 million.
  • Biggest five-year swings in Tax Provisions: skyrocketed 3949.0% in 2021 and later plummeted 965.25% in 2022.
  • Amneal Pharmaceuticals' Tax Provisions stood at $4.1 million in 2021, then tumbled by 142.9% to -$1.8 million in 2022, then surged by 661.85% to $9.9 million in 2023, then crashed by 45.13% to $5.4 million in 2024, then rose by 4.41% to $5.7 million in 2025.
  • The last three reported values for Tax Provisions were $5.7 million (Q4 2025), -$23.4 million (Q3 2025), and $16.1 million (Q2 2025) per Business Quant data.